Sulggi Lee, MD, PhD
Biography
Career Overview
Dr. Lee's career goals are to better understand the association between host genetics and the host immune response to HIV disease using novel genetic and immunologic translational research methods. Specifically, she is interested in 1) understanding the role of host genetics in determining important immunologic markers in HIV disease, e.g., measures of indoleamine 2,3-dioxygenase (IDO) expression in activated monocytes in chronic HIV; and 2) determining the molecular mechanisms by which the innate immune system responds to HIV, e.g., by analyzing gene expression array data in relation to flow cytometry and metabolomics data among specific HIV-infected populations: HIV elite controllers, HIV-suppressed responders, ARV non-responders.
Spotlight: 2018 CFAR Excellence Award Recipient
After graduating from Stanford University, Dr. Lee went on to receive an MD/PhD at the University of Southern California. She has lived in the Bay Area since the third grade though she was born in Naperville, IL, and spent a few years in Sandy, UT. She returned to Stanford for her internal medicine training, followed by an Infectious Disease fellowship at UCSF.
Her impressive training has launched a quickly accelerating career. Her most recent findings set the stage for her next steps, identifying therapeutic approaches to HIV eradication that would combine practical clinical approaches (early HIV treatment) with novel therapeutic target discovery (e.g., host-HIV genetic omics approaches) to potentially apply towards future HIV eradication strategies.
Lee is now working to merge the two studies presented at this conference: 1) a phase IV trial providing immediate antiretroviral therapy to new, acute HIV-infected individuals and following them over time; and 2) a study that will determine whether timing of ART initiation influences where and how frequently HIV integrates into the host genome, potentially influence HIV latency.
When asked how she would define her ultimate achievement in the field of HIV, Lee says contributing to novel and widespread treatments that improve morbidity/mortality in a large number of HIV-infected individuals, is her long-term goal. And contributing, she adds of course, “to an HIV cure.”
Displaying 26 - 46 of 46
- Jonathan Chang, Sulggi Lee, Peter Hunt, Deanna Kroetz, Mark Siedner. Efavirenz-metabolizing polymorphisms, viral suppression, and depression in HIV-infected individuals initiating antiretroviral therapy in southwestern Uganda. Open Forum Infectious Diseases. 2017 Jan 1; 4(suppl_1):s430-s431.
- Hunt PW, Lee SA, Siedner MJ. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016 Oct 01; 214 Suppl 2:S44-50.
- Lee SA, Deeks SG. The Benefits of Early Antiretroviral Therapy for HIV Infection: How Early is Early Enough? EBioMedicine. 2016 Sep; 11:7-8.
- Lee SA, Bacchetti P, Chomont N, Fromentin R, Lewin SR, O'Doherty U, Palmer S, Richman DD, Siliciano JD, Yukl SA, Deeks SG, Burbelo PD. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS One. 2016; 11(8):e0160192.
- Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL. Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS. 2016 07 17; 30(11):1807-15.
- Younes SA, Freeman ML, Mudd JC, Shive CL, Reynaldi A, Panigrahi S, Estes JD, Deleage C, Lucero C, Anderson J, Schacker TW, Davenport MP, McCune JM, Hunt PW, Lee SA, Serrano-Villar S, Debernardo RL, Jacobson JM, Canaday DH, Sekaly RP, Rodriguez B, Sieg SF, Lederman MM. IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. J Clin Invest. 2016 07 01; 126(7):2745-56.
- Ramirez CM, Sinclair E, Epling L, Lee SA, Jain V, Hsue PY, Hatano H, Conn D, Hecht FM, Martin JN, McCune JM, Deeks SG, Hunt PW. Immunologic profiles distinguish aviremic HIV-infected adults. AIDS. 2016 06 19; 30(10):1553-62.http://www.ncbi.nlm.nih.gov/pubmed/24732871
- Freeman ML, Mudd JC, Shive CL, Younes SA, Panigrahi S, Sieg SF, Lee SA, Hunt PW, Calabrese LH, Gianella S, Rodriguez B, Lederman MM. Reply to Barrett, et al. Clin Infect Dis. 2016 06 01; 62(11):1468-9.
- Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015 Dec; 2(12):e520-9.
- Freeman ML, Mudd JC, Shive CL, Younes SA, Panigrahi S, Sieg SF, Lee SA, Hunt PW, Calabrese LH, Gianella S, Rodriguez B, Lederman MM. CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clin Infect Dis. 2016 Feb 01; 62(3):392-6.
- Lee SA. Highlights from the Keystone Symposium on HIV Persistence 2015: 26-30 April 2015, Boston, Massachusetts, USA. J Virus Erad. 2015 Jul 01; 1(3):225-6.
- Lee SA, Plett SK, Luetkemeyer AF, Borgo GM, Ohliger MA, Conrad MB, Cookson BT, Sengupta DJ, Koehler JE. Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification. J Clin Microbiol. 2015 Aug; 53(8):2773-6.
- souheil younes, carey shive, Arnold Reynaldi, Michael Freeman, Soumya Panigrahi, Jacob Estes, Jodi Anderson, Timothy Schacker, Miles Davenport, Joseph McCune, Peter Hunt, Sulggi Lee, Sergio Serrano-Villar, David Canaday, Cheryl Cameron, Rafick-Pierre Sekaly, Benigno Rodriguez, Scott Sieg, Michael Lederman. IL-15 drives CD8 T cell cycling and differentiation in chronic HIV-1 infection (VIR6P.1162). The Journal of Immunology. 2015 May 1; 194(1_Supplement):149.2-149.2.
- Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014 May; 10(5):e1004078.http://www.ncbi.nlm.nih.gov/pubmed/21502083
- Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 01; 210(3):374-82.http://www.ncbi.nlm.nih.gov/pubmed/21402547
- Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, Bangsberg DR, Martin JN, McCune JM, Deeks SG, Hunt PW. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014; 9(2):e89444.http://www.ncbi.nlm.nih.gov/pubmed/21492857
- Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet. 2007 Dec 01; 8:72.
- Anna H. Wu, C. Leigh Pearce, Darcy V. Spicer, Sulggi Lee, Malalcolm C. Pike. Chapter 40 Body weight, menopausal hormone therapy, and risk of breast cancer. Treatment of the Postmenopausal Woman. 2007 Jan 1; (J Natl Cancer Inst481972):569-578.
- Lee SA, Yeka A, Nsobya SL, Dokomajilar C, Rosenthal PJ, Talisuna A, Dorsey G. Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis. 2006 Apr 15; 193(8):1160-3.
- Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2006 Mar 01; 118(5):1285-91.
- Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer. 2005 Jun 06; 92(11):2049-58.